Arcutis Biotherapeutics, Inc.
ARQTDrugs in Pipeline
19
Phase 3 Programs
10
Upcoming Catalysts
1
Next Catalyst
This month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
Topical roflumilast 0.3% foam Phase 2 Est. Readout
Estimated primary completion for Topical roflumilast 0.3% foam trial (NCT07077902) in Hidradenitis Suppurativa. Topline data typically follows completion by weeks to months.
SourceHow ARQT's past catalysts played out
Roflumilast 0.3% cream
Chronic Plaque Psoriasis
Roflumilast Cream 0.05%
Atopic Dermatitis
Roflumilast Foam 0.3%
Scalp Psoriasis
Topical roflumilast
Chronic Plaque Psoriasis
ARQ-151 0.3% cream
Chronic Plaque Psoriasis
Roflumilast Foam
Seborrheic Dermatitis
Roflumilast Cream
Atopic Dermatitis Eczema
ARQ-151 Active
Atopic Dermatitis Eczema
ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%
Atopic Dermatitis Eczema
Roflumilast Cream 0.15%
Atopic Dermatitis Eczema
Roflumilast topical 0.3% foam
Non-segmental Vitiligo
ARQ-252 cream 0.3%
Chronic Hand Eczema
ARQ-151 cream 0.5%
Psoriasis
ARQ-151 cream 0.05%
Atopic Dermatitis (Eczema)
ARQ-151 cream 0.3%
Psoriasis
Roflumilast
Plaque Psoriasis
ARQ-154
Seborrheic Dermatitis
Topical roflumilast 0.3% foam
Hidradenitis Suppurativa
Roflumilast Cream 0.3%
Plaque Psoriasis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Roflumilast 0.3% cream | Phase 3 | Chronic Plaque Psoriasis | - | - |
Roflumilast Cream 0.05% | Phase 3 | Atopic Dermatitis | - | - |
Roflumilast Foam 0.3% | Phase 3 | Scalp Psoriasis | - | - |
Topical roflumilast | Phase 3 | Chronic Plaque Psoriasis | - | - |
ARQ-151 0.3% cream | Phase 3 | Chronic Plaque Psoriasis | - | - |
Roflumilast Foam | Phase 3 | Seborrheic Dermatitis | - | - |
Roflumilast Cream | Phase 3 | Atopic Dermatitis Eczema | - | - |
ARQ-151 Active | Phase 3 | Atopic Dermatitis Eczema | - | - |
ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% | Phase 3 | Atopic Dermatitis Eczema | - | - |
Roflumilast Cream 0.15% | Phase 3 | Atopic Dermatitis Eczema | - | - |
Roflumilast topical 0.3% foam | Phase 2 | Non-segmental Vitiligo | - | - |
ARQ-252 cream 0.3% | Phase 2 | Chronic Hand Eczema | - | - |
ARQ-151 cream 0.5% | Phase 2 | Psoriasis | - | - |
ARQ-151 cream 0.05% | Phase 2 | Atopic Dermatitis (Eczema) | - | - |
ARQ-151 cream 0.3% | Phase 2 | Psoriasis | - | - |
Roflumilast | Phase 2 | Plaque Psoriasis | - | - |
ARQ-154 | Phase 2 | Seborrheic Dermatitis | - | - |
Topical roflumilast 0.3% foam | Phase 2 | Hidradenitis Suppurativa | - | - |
Roflumilast Cream 0.3% | Phase 2 | Plaque Psoriasis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Arcutis Biotherapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 19 drug candidates in Arcutis Biotherapeutics, Inc.'s (ARQT) pipeline across Phase 3, Phase 2. Its lead program is Roflumilast 0.3% cream (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Arcutis Biotherapeutics, Inc.'s next FDA catalyst?→
Arcutis Biotherapeutics, Inc.'s (ARQT) next tracked catalyst is a Phase 2 expected September 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ARQT biotech catalysts?→
Add ARQT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Arcutis Biotherapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.